TMOD2

Across TCGA pan-cancer cohorts, TMOD2 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated TMOD2 data layer compared with 26 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher TMOD2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated TMOD2 expression acts as an unfavorable survival marker, although some lineages such as LUAD and CCRCC show a favorable association.

LUAD, HNSC, and CCRCC are the cancer types where TMOD2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Quartile	All	1.000	0.333	.003	17	view →
HNSC	DFS	Tertile	II,III,IV	0.881	0.991	.013	12	view →
CCRCC	OS	Median	All	0.900	0.782	.018	12	view →
PDAC	DFS	Tertile	All	0.856	0.679	.013	7	view →
LSCC	DFS	Tertile	II,III,IV	0.799	1.000	.012	6	view →
UCEC	DFS	Median	II,III,IV	0.521	0.880	.037	4	view →
GBM	DFS	Tertile	All	0.846	0.643	.029	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

TMOD2–LUAD (DFS)

Open the LUAD breakdown →